Scholars@Duke

• Research
• 

  Selected Grants

  • Determining the clinical efficacy and predictive biomarkers of mirvetuximab soravtansine (IMGN853) in folate receptor alpha (FRA) expressing, chemotherapy refractory triple negative breast cance awarded by National Comprehensive Cancer Network 2016 - 2018

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.